Cyclarity Therapeutics is focused on developing innovative therapies aimed at treating the underlying causes of age-related diseases, particularly atherosclerosis, which is a leading cause of cardiovascular events such as heart attacks and strokes. The company's primary technology involves engineered cyclodextrins, which are polysaccharides designed to target and remove toxic oxidized cholesterol, specifically 7-ketocholesterol, from arterial walls. This approach not only aims to clear existing arterial plaque but also seeks to restore the cardiovascular system's self-repair mechanisms, potentially reversing the progression of atherosclerosis. Cyclarity's lead product, UDP-003, represents a first-in-class drug that utilizes this novel mechanism to provide disease-modifying treatment for cardiovascular diseases.

The Cyclarity Platform is a proprietary discovery tool that combines computational modeling and synthetic chemistry to optimize the design of cyclodextrins for targeted therapeutic applications. This platform allows for extensive virtual experimentation, enabling the identification of effective cyclodextrin candidates that can encapsulate and eliminate harmful cholesterol derivatives. By integrating artificial intelligence into their iterative design process, Cyclarity aims to enhance the efficiency and specificity of their drug development efforts. The company has received recognition for its innovative approach, including an "Innovation Passport" from UK regulators, which facilitates expedited access to clinical trials and regulatory processes.

United States

Cyclarity Therapeutics, Inc. is pursuing a mission to treat, cure, and reverse atherosclerosis. The company aims to deliver simple and affordable therapies for cardiovascular disease and other chronic diseases of aging. Cyclarity is continuing to develop technology to treat the underlying causes of age-related diseases.

Cyclarity Therapeutics

Company Details